SG11201608218QA - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders - Google Patents
2,4-thiazolidinedione derivatives in the treatment of central nervous system disordersInfo
- Publication number
- SG11201608218QA SG11201608218QA SG11201608218QA SG11201608218QA SG11201608218QA SG 11201608218Q A SG11201608218Q A SG 11201608218QA SG 11201608218Q A SG11201608218Q A SG 11201608218QA SG 11201608218Q A SG11201608218Q A SG 11201608218QA SG 11201608218Q A SG11201608218Q A SG 11201608218QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- nervous system
- central nervous
- system disorders
- thiazolidinedione derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 | ||
| PCT/EP2015/057224 WO2015150476A1 (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608218QA true SG11201608218QA (en) | 2016-10-28 |
Family
ID=50513194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608218QA SG11201608218QA (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9782395B2 (en) |
| EP (2) | EP3125888B1 (en) |
| JP (2) | JP6745726B2 (en) |
| KR (1) | KR102418167B1 (en) |
| CN (1) | CN106470991B (en) |
| AU (1) | AU2015239112C1 (en) |
| CA (1) | CA2943373C (en) |
| CL (1) | CL2016002508A1 (en) |
| CY (2) | CY1120454T1 (en) |
| DK (2) | DK3125888T3 (en) |
| EA (2) | EA035866B1 (en) |
| ES (2) | ES2872335T3 (en) |
| HR (2) | HRP20180983T1 (en) |
| HU (2) | HUE039555T2 (en) |
| IL (1) | IL248037B (en) |
| LT (2) | LT3388064T (en) |
| MX (1) | MX2016012687A (en) |
| NZ (1) | NZ725492A (en) |
| PL (2) | PL3125888T3 (en) |
| PT (2) | PT3388064T (en) |
| SG (1) | SG11201608218QA (en) |
| SI (2) | SI3388064T1 (en) |
| WO (1) | WO2015150476A1 (en) |
| ZA (1) | ZA201607286B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| NZ725492A (en) * | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| JP7040798B2 (en) | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 5-[[4- [2- [5- (1-hydroxyethyl) pyridin-2-yl] ethoxy] phenyl] methyl] -1,3-thiazolidine-2 for treating non-alcoholic fatty liver disease ， 4-Zeon |
| PL3559010T3 (en) | 2016-12-23 | 2022-11-21 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
| WO2019234664A1 (en) | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| BR112020024917A2 (en) | 2018-06-06 | 2021-03-09 | Minoryx Therapeutics S.L. | METHOD OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5 - [[4- [2- [5- (1-HYDROXYETHIL) PIRIDIN-2-IL] ETOXI] PHENYL] METHIL] -1,3-THIAZOLIDINE-2,4-DIONA |
| WO2019234690A1 (en) | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
| CN116390725A (en) | 2020-04-30 | 2023-07-04 | 米尼奥尔克斯治疗有限公司 | Hydroxy pioglitazone for treating pulmonary inflammation and interstitial lung disease |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1743292A (en) * | 1991-04-11 | 1992-11-17 | Takeda Chemical Industries Ltd. | Thiazolidinedione derivatives, production and use thereof |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| AU4104593A (en) * | 1992-05-05 | 1993-11-29 | Upjohn Company, The | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| JP2005514399A (en) | 2001-12-21 | 2005-05-19 | スミスクライン ビーチャム コーポレーション | Dosage of PPARγ activator |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| WO2005016339A1 (en) * | 2003-07-24 | 2005-02-24 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| CN101454005B (en) | 2006-03-16 | 2013-01-02 | 新陈代谢解决方案开发公司 | Thiazolidinedione analogues for the treating metabolic inflammation mediated disease |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| RU2570424C2 (en) * | 2009-12-15 | 2015-12-10 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Ppar-supporting thiazolidinediones and their combinations for treatment of neurodegenerative diseases |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US20150224120A1 (en) | 2011-09-14 | 2015-08-13 | Catherine Clelland | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) * | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| CA2941562C (en) * | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| NZ725492A (en) * | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
-
2015
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 ES ES18173541T patent/ES2872335T3/en active Active
- 2015-04-01 SI SI201531591T patent/SI3388064T1/en unknown
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en active Application Filing
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/en unknown
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 MX MX2016012687A patent/MX2016012687A/en active IP Right Grant
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/en unknown
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/en active Active
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/en active
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 PL PL15713499T patent/PL3125888T3/en unknown
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/en unknown
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/en active IP Right Grant
- 2015-04-01 PT PT181735416T patent/PT3388064T/en unknown
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/en active Active
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/en active Active
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/en unknown
- 2015-04-01 PL PL18173541T patent/PL3388064T3/en unknown
- 2015-04-01 EA EA201691997A patent/EA035866B1/en unknown
- 2015-04-01 PT PT157134990T patent/PT3125888T/en unknown
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
- 2015-04-01 EA EA202091120A patent/EA202091120A3/en unknown
-
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/en unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
-
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
-
2018
- 2018-06-26 HR HRP20180983TT patent/HRP20180983T1/en unknown
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/en unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/en active Pending
-
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/en unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210518T1 (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| PL3160464T3 (en) | 6-hydroxybuspirone for use in the treatment of movement disorders | |
| HK1216641A1 (en) | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders 123--4- | |
| SI3452465T1 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| IL249502B (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| PL3148990T3 (en) | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | |
| HRP20181123T1 (en) | 3,4-diamino-6-chloropyrazine-2-carboxamide compounds for the treatment of enac mediated diseases | |
| PT3148990T (en) | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | |
| GB201602011D0 (en) | Treating skin disorders | |
| TH1601002629A (en) | Pyrido[4,3-B]pyrazine-2-carboxamide in the form of nerve-producing substances for Treatment of neurodegenerative disorders | |
| GB201413533D0 (en) | Combination therapy for treating disorders of the vestibular system | |
| GB201416044D0 (en) | The way, Mental Health Therapeutic Technique |